Summary of Key Points Core Viewpoint - Swire Properties A has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent declines [2][3]. Share Buyback Activity - The company repurchased 210,000 shares on April 29 at prices ranging from HKD 65.700 to HKD 66.750, totaling HKD 13.9023 million [2]. - Since March 13, the company has conducted buybacks for 31 consecutive days, acquiring a total of 10.9975 million shares for a cumulative amount of HKD 733 million [2]. - The stock has experienced a cumulative decline of 6.73% during this buyback period [2]. Year-to-Date Buyback Summary - Year-to-date, Swire Properties A has completed 76 buyback transactions, acquiring a total of 22.298 million shares for a total expenditure of HKD 1.482 billion [3]. - The buyback details include various dates, share quantities, and price ranges, reflecting a consistent effort to stabilize the stock price [3][4][5].

证券时报·数据宝统计，上海石油化工股份在港交所公告显示，4月29日以每股1.150港元至1.160港元的 价格回购282.00万股，回购金额达324.61万港元。该股当日收盘价1.150港元，下跌0.86%，全天成交额 1115.77万港元。 自4月24日以来公司已连续4日进行回购，合计回购1036.80万股，累计回购金额1198.98万港元。 其间该 股累计下跌4.96%。 今年以来该股累计进行26次回购，合计回购5134.40万股，累计回购金额6009.45万港元。（数据宝） 上海石油化工股份回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.04.29 | 282.00 | 1.160 | 1.150 | 324.61 | | 2025.04.28 | 232.40 | 1.170 | 1.150 | 268.40 | | 2025.04.25 | 208.40 | 1.180 | 1.160 | 242.89 | | 2025.04.24 | 314.00 | ...

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.04.29 | 100.00 | 4.310 | 4.280 | 429.61 | | 2025.04.28 | 100.00 | 4.400 | 4.340 | 437.24 | | 2025.04.25 | 100.00 | 4.390 | 4.300 | 434.61 | | 2025.04.24 | 100.00 | 4.300 | 4.240 | 428.32 | | 2025.04.16 | 100.00 | 4.460 | 4.370 | 441.02 | | 2025.04.15 | 150.00 | 4.400 | 4.350 | 656.50 | | 2025.04.14 | 150.00 | 4.400 | 4.350 | 655.73 | | 2025.04.11 | 49.00 | 4.370 | 4.360 | 214.13 | | 2025.04.10 | 150.00 | 4.300 | 4.2 ...

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.04.29 | 120.00 | 6.770 | 6.570 | 804.73 | | 2025.04.28 | 44.40 | 6.580 | 6.370 | 291.34 | | 2025.04.25 | 99.90 | 6.440 | 6.410 | 643.05 | | 2025.04.22 | 11.10 | 5.930 | 5.880 | 65.72 | | 2025.04.17 | 176.70 | 5.840 | 5.770 | 1029.67 | | 2025.04.16 | 23.70 | 5.680 | 5.590 | 134.14 | | 2025.04.15 | 5.10 | 5.510 | 5.480 | 28.06 | | 2025.04.10 | 198.60 | 5.370 | 5.200 | 1062.49 | | 2025.04.09 | 389.70 | 5.270 | 4.850 | ...

Core Viewpoint - Mengniu Dairy has been actively repurchasing its shares, indicating a strategy to enhance shareholder value and confidence in its stock performance [2] Summary by Category Share Buyback Activity - On April 29, Mengniu Dairy repurchased 200,000 shares at a price range of HKD 18.940 to HKD 19.200, totaling HKD 3.8077 million [2] - The stock closed at HKD 19.020 on the same day, reflecting a decrease of 0.31% with a total trading volume of HKD 193 million [2] - Year-to-date, the company has conducted 15 buybacks, acquiring a total of 3.89 million shares for a cumulative amount of HKD 67.5025 million [2] Detailed Buyback Information - The buyback details are as follows: - April 29: 20,000 shares at a maximum price of HKD 19.200 and a minimum of HKD 18.940, amounting to HKD 3.8077 million - April 25: 20,000 shares at a maximum price of HKD 19.300 and a minimum of HKD 19.160, amounting to HKD 3.8495 million - April 24: 20,000 shares at a maximum price of HKD 19.200 and a minimum of HKD 19.120, amounting to HKD 3.8337 million - April 22: 30,000 shares at a maximum price of HKD 19.300 and a minimum of HKD 19.100, amounting to HKD 5.7650 million - April 17: 20,000 shares at a maximum price of HKD 19.500 and a minimum of HKD 19.460, amounting to HKD 3.8957 million - April 8: 15,000 shares at a maximum price of HKD 18.900 and a minimum of HKD 18.700, amounting to HKD 2.8225 million - April 7: 80,000 shares at a maximum price of HKD 17.980 and a minimum of HKD 17.640, amounting to HKD 14.2882 million - January 16: 46,000 shares at a maximum price of HKD 14.980 and a minimum of HKD 14.860, amounting to HKD 6.8767 million - January 10: 13,000 shares at a maximum price of HKD 15.320 and a minimum of HKD 15.280, amounting to HKD 1.9906 million - January 9: 12,000 shares at a maximum price of HKD 16.040, amounting to HKD 1.9248 million - January 8: 30,000 shares at a maximum price of HKD 16.100 and a minimum of HKD 16.060, amounting to HKD 4.8262 million - January 7: 18,000 shares at a maximum price of HKD 16.440 and a minimum of HKD 16.240, amounting to HKD 2.9470 million - January 6: 30,000 shares at a maximum price of HKD 16.260 and a minimum of HKD 16.200, amounting to HKD 4.8710 million - January 3: 18,000 shares at a maximum price of HKD 16.400 and a minimum of HKD 16.340, amounting to HKD 2.9472 million - January 2: 17,000 shares at a maximum price of HKD 17.020 and a minimum of HKD 16.680, amounting to HKD 2.8567 million [2]

Core Viewpoint - The company has shown steady operational improvement in Q1 2025, with significant increases in revenue and profit compared to the same period last year Group 1: Financial Performance - The company's revenue increased by approximately 16.1% year-on-year for the three months ending March 31, 2025, while profit rose by about 14.3% [1] - Profit attributable to ordinary shareholders increased by approximately 16.7% compared to the same period last year [1] Group 2: Comprehensive Medical Services - The company has focused on improving the quality and efficiency of comprehensive medical services amidst external challenges such as payment reforms and strict management of medical insurance funds [1] - The overall operational status of the company's medical institutions was good, with outpatient and emergency visits increasing by about 2.3% year-on-year [1] - The average length of hospital stay decreased to 9.2 days, indicating improved operational efficiency [1] - Medical service revenue accounted for 35.6% of total revenue, up by 2.5 percentage points year-on-year, reflecting an optimized revenue structure [1] - The proportion of drug costs to revenue decreased from 46.5% to 43.7%, demonstrating effective cost control [1] Group 3: Specialized Medical and Health Technology - The company is pursuing a dual strategy of intrinsic development and external expansion in specialized medical and health technology [2] - The acquisition of Beijing Jinxu Medical Instrument Co., Ltd. was completed, enhancing the company's capabilities in medical endoscopy and related services [2] - This acquisition addresses challenges related to high asset values and maintenance costs in the company's managed services for medical endoscopes [2] - The company has expanded its market presence and improved its integration with regional governments following the acquisition of Shandong Qingniao Soft Communication Co., Ltd. [2] Group 4: Financial Business - The company is committed to serving the real economy and advancing its financial business transformation [3] - It is transitioning towards four key areas: health and wellness, equipment manufacturing, chemical pharmaceuticals, and innovative businesses [3] - The company has introduced a new model combining "financing leasing + full lifecycle management" for medical equipment [3] - The company has effectively controlled overall financing costs while ensuring adequate liquidity and stable debt structure [3] - As of March 31, 2025, the total interest-earning assets have continued to grow, with stable improvements in net interest margin and net profit margin [3]

智通财经APP获悉，4月30日，云顶新耀(01952)今日宣布，中国香港卫生署已正式批准伊曲莫德 (VELSIPITY®，etrasimod)用于治疗中重度活动性溃疡性结肠炎(UC)成人患者的新药上市许可申请。继 中国澳门和新加坡之后，中国香港成为伊曲莫德在云顶新耀授权区域内第三个获批的地区。2024年12 月，伊曲莫德(维适平TM)的新药上市申请获得中国国家药品监督管理局的正式受理。 伊曲莫德是一款每日一次口服的一线先进疗法，不仅使用方便、疗效佳，而且具有良好的安全性特征。 此次获批是基于ELEVATE UC III期注册研究(ELEVATE UC 52和ELEVATE UC 12)的结果。这两项随 机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，安全性特征与既往研究一致。此前，伊 曲莫德已被纳入2024年美国胃肠病学协会(AGA)临床实践指南, 作为溃疡性结肠炎的一线治疗。 云顶新耀首席执行官罗永庆表示："非常高兴看到伊曲莫德的新药上市申请在中国香港获批。2022年， 中国的溃疡性结肠炎患者数量约为60万人，预计到2030年将达到100万人，存在迫切且巨大的未被满足 的临床需求。我们始终致力于提升 ...

不俗的业绩表现，让阳光保险在资本市场也颇受青睐。进入2025年以来股价由2.75港元涨至4月27日收盘的3.50港元，涨幅达27.2%。一举扭转2024年全年 股价下跌35%的局面，作为一家国内知名民营保险服务集团，阳光保险自2022年12月9日上市后，股价就一路走低，长期在低位徘徊，相较上市发行价 5.83港元，下跌40%，市值蒸发超200亿港元。但进入2025年其股价明显回暖。截至4月27日收盘，阳光保险最新市值为402.6亿港元。 | | 今开:3.480 最高:3.620 成交量:857.5万 内盘: | | --- | --- | | 阳光保险 06963.hk 3.5004 +0.020 +0.575% | 昨收:3.480 最低:3.450 成交额:3011万 外盘: | 近期#阳光保险董事长拉员工开会到凌晨#话题登上热搜，引发网友热议。 同期中国人寿市值为1.032万亿元，中国平安市值9437亿元，中国人保市值3184亿元，中国太保市值2965亿元……在2024年《财富》中国500强榜单中，阳 光保险位列第313位，较上年提升明显，整体实力和头部险企差距较大。 阳光保险近日内部发通知称，张维功 ...

Core Viewpoint - The company, Xintian Green Energy, has released its first quarter report for 2025, highlighting significant changes in operational metrics and financial data, while ensuring the accuracy and completeness of the information provided [1][12][16]. Financial Data Summary - The first quarter financial report is not audited [2]. - The company reported a total power generation of 4,544,188.70 MWh, an increase of 10.37% year-on-year [8]. - The total on-grid electricity reached 4,442,621.49 MWh, reflecting a year-on-year increase of 10.45% [8]. - The average on-grid electricity price (excluding tax) was 0.43 RMB/kWh, unchanged from the previous year [8]. - Market-based electricity trading volume was 1,986,200.29 MWh, with a trading volume ratio of 44.71%, up by 9.04 percentage points year-on-year [8]. Gas Transmission and Sales Summary - The total gas transmission/sales volume was 184,698.01 million cubic meters, a decrease of 17.18% year-on-year [9]. - The sales volume was 168,417.04 million cubic meters, down by 15.23% year-on-year [9]. - The gas transmission volume was 16,280.97 million cubic meters, showing a significant decrease of 33.13% year-on-year [9]. Shareholder Information - As of March 31, 2025, the total number of shareholders was 43,628, with 42,490 A-share shareholders and 1,138 H-share shareholders [3]. Board and Supervisory Meetings - The board of directors held a meeting on April 29, 2025, where the first quarter report was approved unanimously [11][12]. - The supervisory board also convened on the same day and approved the first quarter report, confirming its compliance with legal and regulatory requirements [14][16].

金十数据4月30日讯，融创服务(01516.HK)公告，为进一步优化战略布局，将更多资源与管理精力聚焦 投入在一二线核心城市，于2025年4月29日，本公司之全资附属公司融远投资与广西老彰家等订立股权 交易协议，以实现本集团全面退出彰泰服务集团。据此，融远投资将其间接持有的广西彰泰融创智慧 80%股权，以代价人民币8.2662亿元，通过相关交易安排转让给广西老彰家。本次交易完成后，本集团 将不再持有彰泰服务集团任何权益。 融创服务：以8.26亿元出售彰泰融创智慧80%股权 ...